| Chief Investigator: |
Professor Hisham Mehanna |
| Sponsor: |
University of Birmingham |
| Funders: |
Cancer Research UK, Clinical Trials Awards & Advisory Committee (CTAAC) |
| Disease Site: |
Head and Neck |
| Trial Type: |
Clinical Trial of Investigational Medicinal Products/ Radiotherapy/ Surgical Trial |
| Status: |
Open |
| UKCRN Study ID: (if applicable) |
18621 |
| Open to new sites? |
Yes |
| Recruitment start date: |
6th July 2015 |
| Anticipated Recruitment end date |
September 2023 |
| CRCTU Trial Management Team: |
B Team |
| Trial E-mail Address: |
CompARE@trials.bham.ac.uk |
Trial Summary
The CompARE study has been set up to investigate which treatment is most effective for patients who have higher-risk oropharyngeal cancer. The purpose of this study is to consider using additional treatments in conjunction with standard chemoradiotherapy to increase cure rates of higher-risk oropharyngeal cancer. This will be done by adding surgery or immunotherapy or more chemotherapy or higher dose radiotherapy to the standard chemoradiotherapy. Immunotherapy is novel approach, which uses drugs that encourages the body's natural defence system, the immune system to attack cancer cells.
Please note that the trials team cannot give individuals clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible.
Trial Protocol
Please note: Clinical trial protocols are complex technical documents, which should only be used for the treatment of subjects taking part in the trial. Patients who are interested in taking part in the trial are advised to talk to their health care professional or refer to the CancerHelp website
To view the Protocol and other trial related documents, please refer to the Investigators page.
Investigators please ensure you have R&D approval for this specific version of the protocol before using as a reference.